Abstract
Vaccine efficacy largely depends upon DC targeting and activation. The most potent TLR soluble ligands induce diffuse DC activation, which may be associated with marked pro-inflammatory responses and possibly adverse effects. This raises the concern that effective vaccine adjuvants may similarly rely on widespread DC activation. Using a promising candidate vaccine against tuberculosis (fusion protein of Ag85B and 6-kDa early secretory antigenic target (ESAT-6)) formulated in the potent IC31 adjuvant, DC targeting and activation was studied in vivo, following the fate of antigen and adjuvant in the draining lymph nodes, to define the magnitude of DC targeting/activation required in vivo to induce protective vaccine responses. Unexpectedly, protective IFN-gamma-mediated Ag85B-ESAT-6/IC31 responses were associated to the activation of a minute population (less than 0.3%) of CD11c(+) lymph node DC, without detectable systemic pro-inflammatory responses. This activated peripheral tissue-derived DC population, characterized by enhanced CD80, CD86, CD40 and IL-12p40 expression, was only identified when focusing on adjuvant- or antigen-labeled CD11c(+) DC, which were found to support T cell proliferation. Immunization with aluminum hyd...Continue Reading
References
Apr 25, 2000·Vaccine·N PuriP J Sinko
Jun 6, 2000·Advanced Drug Delivery Reviews·R K Gupta
Oct 25, 2000·The Journal of Immunology : Official Journal of the American Association of Immunologists·C RuedlK Karjalainen
Apr 9, 2001·Infection and Immunity·A Weinrich OlsenP Andersen
Apr 21, 2001·The Journal of Immunology : Official Journal of the American Association of Immunologists·P LenzJ T Schiller
Jun 19, 2001·Current Opinion in Immunology·A Lanzavecchia, F Sallusto
Jul 7, 2001·The Journal of Immunology : Official Journal of the American Association of Immunologists·S HenriK Shortman
Feb 28, 2002·Annual Review of Immunology·Arthur M Krieg
Jun 18, 2002·Infection and Immunity·Caroline RoduitClaire-Anne Siegrist
Feb 4, 2003·Nature Reviews. Immunology·Giorgio Trinchieri
Feb 8, 2003·Virology·Xavier MartinezClaire-Anne Siegrist
Jul 23, 2003·Immunity·Andrea A ItanoMarc K Jenkins
Aug 28, 2003·Immunology·Neil C RobsonAllan McI Mowat
Feb 24, 2004·Infection and Immunity·L Holten-AndersenP Andersen
Apr 2, 2004·Nature Reviews. Immunology·Dennis M Klinman
May 11, 2004·Nature Immunology·Wu-Shiun Hou, Luk Van Parijs
Jun 15, 2004·Vaccine·Praveen ElamanchiliJohn Samuel
Aug 17, 2004·Vaccine·Jörg H FritzWolfgang Zauner
Jan 7, 2005·The Journal of Immunology : Official Journal of the American Association of Immunologists·Arun T KamathDavid F Tough
Apr 7, 2005·Nature Medicine·Achal PashineJeffrey B Ulmer
Nov 23, 2005·The Journal of Immunology : Official Journal of the American Association of Immunologists·Anna SkoweraMark Peakman
Feb 8, 2006·The Journal of Experimental Medicine·Troy QuerecBali Pulendran
May 5, 2006·European Journal of Immunology·Karine SerrePatrick Machy
May 6, 2006·Vaccine·Else Marie AggerPeter Andersen
May 9, 2006·Vaccine·Carola SchellackKaren Lingnau
Oct 20, 2006·Trends in Immunology·Sai T ReddyJeffrey A Hubbell
Dec 16, 2006·Nature Reviews. Immunology·Ken Shortman, Shalin H Naik
Feb 17, 2007·Immunology·Karen Smith KorsholmPeter Andersen
Mar 14, 2007·Nature Immunology·Shabaana A KhaderAndrea M Cooper
Citations
Nov 19, 2011·Cancer Immunology, Immunotherapy : CII·Jon HansenElse Marie Agger
Sep 16, 2009·Infection and Immunity·Timothy S C HinksAjit Lalvani
Sep 9, 2008·PloS One·Else Marie AggerPeter Andersen
Nov 11, 2008·PloS One·Arun T KamathClaire-Anne Siegrist
Jun 6, 2009·PloS One·Arun T KamathClaire-Anne Siegrist
Feb 14, 2013·PloS One·Attila SzaboEva Rajnavolgyi
Oct 17, 2013·PloS One·Laura MarongiuStefano Dusi
May 23, 2015·Human Vaccines & Immunotherapeutics·Sepideh AboutorabianRoger H Brookes
May 7, 2016·Vaccines·Ghania ChikhRisini D Weeratna
Jul 5, 2008·Drug Discovery Today·Richard W Titball
Sep 15, 2009·Vaccine·Nicholas J SteersMangala Rao
Dec 14, 2016·Scientific Reports·Thorunn A OlafsdottirAli M Harandi
Nov 21, 2009·Clinics in Chest Medicine·Paul-Henri LambertWillem A Hanekom
Mar 14, 2009·Scandinavian Journal of Immunology·T A OlafsdottirI Jonsdottir
Feb 27, 2010·European Journal of Immunology·Rolf BilleskovJes Dietrich
Apr 22, 2011·Expert Review of Vaccines·Virgil E J C Schijns, Ed C Lavelle
Jan 10, 2019·ILAR Journal·Signe Tandrup SchmidtDennis Christensen
Jul 4, 2020·Journal of Leukocyte Biology·Tamara Silva RodriguesVânia Luiza Deperon Bonato
Sep 5, 2018·Frontiers in Microbiology·Louis R JoslynDenise E Kirschner
Apr 17, 2012·The Journal of Immunology : Official Journal of the American Association of Immunologists·Arun T KamathClaire-Anne Siegrist
Mar 16, 2018·Frontiers in Immunology·Maria VonoClaire-Anne Siegrist
Aug 23, 2018·Scientific Reports·Charles B ChessonJai S Rudra
May 18, 2011·Bioconjugate Chemistry·Hubert F GaertnerOliver Hartley
Jan 20, 2009·Vaccine·Anita H J van den BiggelaarPatrick G Holt
Sep 6, 2011·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Camilla FogedElse Marie Agger
Nov 26, 2015·Advanced Drug Delivery Reviews·Else Marie Agger